In a landmark decision that illuminates the cutting-edge world of biotech, the European Commission (EC) has granted Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) approval to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and potentially fatal heart disease. This green light was given following the promising results shown in the HELIOS-B trial, which included a diverse patient population […]
Category: Alnylam Pharmaceuticals
Insights on Alnylam Pharmaceuticals from 18 Analyst Ratings
Alnylam Pharmaceuticals, a trailblazer in the realm of RNA interference (RNAi) therapeutics, is leveraging a natural biological process—gene expression regulation—to revolutionize the treatment of rare diseases. With five commercially available drugs and an array of clinical programs spanning multiple therapeutic areas, Alnylam stands at the forefront of biopharmaceutical innovation. The company’s financial stability, bolstered by […]
Analyst Ratings Analysis for Alnylam Pharmaceuticals
In the realm of biotechnology, the dazzling science of gene regulation has been revolutionizing the medical landscape. At the heart of this evolution, Alnylam Pharmaceuticals has been carving out its reputation as an innovator par excellence, with a keen focus on RNA interference (RNAi) therapeutics. The company, renowned for its pioneering work in genetic medicine, […]
Court Confirms Moderna’s Victory Over Alnylam’s ‘Branched Alkyl’
In a landmark decision that could have profound implications for future patent disputes, the Court of Appeals for the Federal Circuit (CAFC) has made a significant clarification on the strict interpretation of the term ‘unless otherwise specified’ in patent claims. This precedential decision, issued on June 4, 2025, affirmed a district court’s finding of noninfringement […]
US Appeals Court Rules in Favor of Moderna’s COVID Patent Claims
In a significant legal decision, a US appeals court has sided with Moderna on their COVID patent claims. Moderna, a prominent biotech company, has been at the forefront of developing mRNA-based vaccines for COVID-19. This ruling reinforces the company’s intellectual property rights and may have broader implications for the biotech industry’s approach to vaccine development. […]
